Journal
LANCET DIABETES & ENDOCRINOLOGY
Volume 6, Issue 5, Pages 404-415Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/S2213-8587(17)30401-1
Keywords
-
Categories
Funding
- Novartis
- Ipsen
- Roche
Ask authors/readers for more resources
In this Review, we discuss clinical developments and controversies in the treatment of neuroendocrine tumours (NETs) that are relevant for clinicians and clinical researchers. We describe advances in genetics, blood-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of recent phase 3 studies, systemic treatment of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemotherapy, and molecularly targeted therapy, and the potential role of immunotherapy in the treatment of NETs. Suggested treatment algorithms for NETs of ileal or jejunal origin and of pancreatic origin are presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available